Fioricet is a prescription combination of butalbital, acetaminophen and caffeine, used mainly for tension headaches. Butalbital is the piece of that formula that matters for drug testing. It is a barbiturate, and barbiturates are their own screening category, separate from opioids, amphetamines, benzodiazepines and THC. Whether Fioricet shows up on a test depends entirely on whether the panel includes a barbiturate (BAR) target. Many workplace and clinical panels do not. Expanded panels built for pain management, drug diversion monitoring or clinical toxicology often do.
What Is in Fioricet
The current FDA label for a butalbital, acetaminophen and caffeine capsule product lists each active ingredient and its disposition in the body. Butalbital has a reported elimination half life of about 35 hours, acetaminophen's half life is roughly 1.25 to 3 hours, and caffeine's is about 3 hours, according to the prescribing information posted on DailyMed, the National Library of Medicine's repository of FDA drug labeling. Because butalbital clears far more slowly than the other two ingredients, it is the component a drug test panel is actually built to detect, and the one that stays measurable the longest after a dose.
Butalbital Is a Barbiturate Under Federal Law, With a Narrow Carve Out for the Finished Product
Barbiturates are regulated under the Controlled Substances Act. Schedule III under the Drug Enforcement Administration's own regulations covers "any substance which contains any quantity of a derivative of barbituric acid or any salt thereof," language that is broad enough to reach butalbital as a chemical class. That paragraph is published at 21 CFR 1308.13(c)(3), Schedule III, as reproduced by the Government Publishing Office.
At the same time, the DEA maintains a separate list of exempted prescription products, finished combination drugs that mix a Schedule III or Schedule V controlled ingredient with other active ingredients that are not themselves scheduled. Products that match an approved formula on that list are administratively exempted from several Controlled Substances Act registration and distribution provisions, though the regulation specifically carves butalbital products back out of the exemption for import, export and in-transit shipment controls. The rule is published at 21 CFR 1308.32, Exempted Prescription Products. In practice this means a specific, approved butalbital combination capsule can sit in an unusual federal regulatory position, while the active ingredient itself remains a barbiturate for every purpose that matters to a drug test. It also means state law can and does diverge, since many states schedule butalbital combination products as controlled substances in their own right regardless of the federal administrative exemption. Employers and screeners should not treat the federal exemption as meaning the drug is unregulated or untestable.
How a Barbiturate Immunoassay Actually Works
A BAR panel on a urine cup, dip card or lab immunoassay is a screening test. It uses antibodies built to react with the barbiturate class as a chemical group, not with butalbital by name. A positive screen means the sample contains enough of a cross reactive barbiturate metabolite to clear the device or assay's cutoff. It does not identify which specific barbiturate is present, and it is not a legal or medical determination on its own. Any presumptive positive on a regulated or employment test is supposed to move to confirmatory testing by gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry, which identifies the exact compound and quantifies it. Only the confirmed, quantified result goes to a medical review officer for interpretation.
Cutoff concentrations for non federal barbiturate panels are set by the device manufacturer or the testing laboratory, not by a single federal rule, so they vary by product and by lab. Employers and clinics running a BAR panel should check the specific cutoff in the manufacturer's package insert or the laboratory's validated reporting limit rather than assume a single number applies everywhere.
Is Butalbital on the Federal Workplace Panel
No. The federally mandated panel for safety sensitive transportation employees under Department of Transportation rules, and the panel used across most other federal workplace drug testing programs, covers marijuana metabolites, cocaine metabolite, opioids (codeine, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, 6-acetylmorphine), phencyclidine, amphetamine and methamphetamine, and MDMA and MDA. Barbiturates are not an analyte on that list. The initial and confirmatory test cutoffs for the federal panel are published at 49 CFR 40.85, which sets the DOT urine drug testing cutoff table, and the broader Mandatory Guidelines for Federal Workplace Drug Testing Programs are maintained by the Substance Abuse and Mental Health Services Administration at SAMHSA's federal workplace drug testing program page. A positive Fioricet prescription will not trigger a false mark against the federal five analyte panel, because butalbital is not one of the analytes that panel is built to find.
Employers who want barbiturate coverage have to choose a panel that explicitly adds a BAR line, which is common on expanded 10, 12 or higher panel cups and dip cards used outside the strict DOT context, and in pain management and clinical settings where a prescriber wants to confirm a patient is taking what was prescribed, and nothing else.
Barbiturates Commonly Covered by a BAR Panel
| Barbiturate | DEA schedule (active ingredient) | Typical clinical use | Detection note |
|---|---|---|---|
| Butalbital (in Fioricet) | Schedule III as a barbituric acid derivative; the specific combination capsule sits on the DEA's exempted prescription product list | Tension headache combination product | Elimination half life about 35 hours per the product's own labeling; detectable on a BAR screen for one to several days after the last dose, longer with frequent or heavy use |
| Phenobarbital | Schedule IV | Seizure disorders | Long acting; can remain detectable for a week or more, see our dedicated phenobarbital post |
| Secobarbital | Schedule II | Short term insomnia (rarely prescribed now) | Short acting; narrower detection window than butalbital or phenobarbital |
| Pentobarbital | Schedule II (some formulations) | Sedation, veterinary euthanasia use | Short to intermediate acting |
| Amobarbital | Schedule II | Historic sedative, now rarely used clinically | Intermediate acting |
Detection windows above are general ranges, not promises. Actual time to a negative result depends on dose, frequency of use, individual metabolism, hydration, and the specific cutoff the testing device or laboratory uses. The National Institute on Drug Abuse describes barbiturates as a depressant drug class with this kind of variability in its public drug information resource, available through NIDA's commonly used drugs reference, and the National Library of Medicine's consumer testing overview covers how barbiturate and benzodiazepine panels fit into a standard drug test at MedlinePlus, Drug Testing.
What Happens If a Barbiturate Screen Comes Back Positive
A single immunoassay result should never be treated as final. The correct sequence is a positive screen, a GC/MS or LC/MS/MS confirmation at a certified laboratory, and medical review officer interpretation before any report reaches an employer or program administrator. If a person is taking Fioricet under a valid prescription, that documentation goes to the MRO, not to the collection site and not to a manager. A documented, current prescription that matches the confirmed analyte is the standard basis for an MRO to report the result as not verified positive, but that determination belongs to the MRO, not to a supervisor, a desk clerk, or the person being tested. Nobody involved in collecting or reading a screening device should be giving dosing advice, confirming whether a specific prescription will clear review, or recommending how to avoid a positive result. That interpretation step is the entire reason the MRO role exists.
Clinics running compliance or pain management monitoring, rather than pre employment screening, typically want a BAR line specifically so a prescribed butalbital combination shows up and confirms adherence, the opposite goal from a workplace program trying to catch misuse. Both use cases depend on the same screen, confirm, review sequence.
Choosing a Panel for Barbiturate Coverage
If a program needs to see barbiturates at all, that requirement has to be built into the panel selection up front. A standard federal five panel configuration will not show butalbital, phenobarbital, or any other barbiturate, by design. Programs that need that coverage should look at expanded multi panel cups or dip cards that list BAR as one of the included analytes, verify the manufacturer's stated cutoff, and route any non negative result through confirmation and MRO review the same way any other presumptive positive is handled. American Screening Corporation's drug test cup collection includes configurations with barbiturate coverage for employers and clinics that want it. For more on how barbiturates behave across the panel generally, see our related post on barbiturate detection times on a drug test, and for a look at a single, long acting barbiturate often confused with butalbital, see does phenobarbital show up on a drug test.
Frequently asked questions
Does Fioricet show up as an opiate or amphetamine on a drug test?
No. Fioricet's active drug component for testing purposes is butalbital, a barbiturate. It does not cross react with opiate, amphetamine, benzodiazepine or THC immunoassays. It can only show up on a panel that includes a barbiturate (BAR) target.
Will Fioricet cause a positive on the standard federal five panel drug test?
No. The federal panel used for DOT regulated testing and most other federal workplace programs does not include barbiturates as an analyte, as set out in 49 CFR 40.85. A barbiturate will only appear on a panel that specifically adds BAR coverage.
How long does butalbital stay detectable in urine after taking Fioricet?
It varies by dose, frequency of use and individual metabolism. Butalbital's labeled elimination half life is about 35 hours, which generally supports detection on a barbiturate screen for roughly one to several days after the last dose, longer with frequent or higher dose use. Ask the testing laboratory for its specific cutoff and reporting window.
Is butalbital a controlled substance?
As a chemical class, barbituric acid derivatives including butalbital fall under Schedule III of the Controlled Substances Act. The specific finished combination product matching an approved formula may appear on the DEA's exempted prescription products list, which changes some federal administrative requirements but does not change state scheduling, which varies, or the need to document a valid prescription if a screen comes back positive.
What should happen if an employee tests positive for barbiturates while taking prescribed Fioricet?
The screening result should go to confirmatory GC/MS or LC/MS/MS testing, then to a medical review officer along with the employee's prescription documentation. The MRO, not the collection site or the employer, makes the final call on whether the result is reported as verified positive.
Can a lab tell the difference between butalbital and other barbiturates on a drug test?
The initial immunoassay screen generally cannot. It detects the barbiturate class as a group. Confirmatory testing by gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry identifies and quantifies the specific barbiturate present.
This article is general information about drug testing science and panel design, not legal or medical advice. Employers and clinics should work with a medical review officer and qualified counsel on specific testing decisions.
